{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:02:41Z","timestamp":1780527761819,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.ygyno.2008.01.008","type":"journal-article","created":{"date-parts":[[2008,2,15]],"date-time":"2008-02-15T12:44:10Z","timestamp":1203079450000},"page":"140-145","source":"Crossref","is-referenced-by-count":39,"title":["Cyclooxygenase-2 in cervical neoplasia: A review"],"prefix":"10.1016","volume":"109","author":[{"given":"Jennifer L.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Darus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Modesitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2008.01.008_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2008.01.008_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jnci\/djj339","article-title":"Stat bite: worldwide cervical and uterine cancer incidence and mortality, 2002","volume":"98","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2008.01.008_bib3","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/01.inf.0000196485.86376.46","article-title":"Advances in prevention of cervical cancer and other human papillomavirus-related diseases","volume":"25","author":"Frazer","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 1","key":"10.1016\/j.ygyno.2008.01.008_bib4","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jcv.2004.12.008","article-title":"The epidemiology of human papillomavirus infections","volume":"32","author":"Baseman","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.5858\/2000-124-0672-QMIGCU","article-title":"Quality management in gynecologic cytology using interlaboratory comparison","volume":"124","author":"Jones","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ygyno.2008.01.008_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/oxfordjournals.jncimonographs.a003478","article-title":"Chapter 4: genital tract infections, cervical inflammation, and antioxidant nutrients\u2014assessing their roles as human papillomavirus cofactors","author":"Castle","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2008.01.008_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ncponc0081","article-title":"Mechanisms of disease: inflammation and the origins of cancer","volume":"2","author":"Moss","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib8","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1158\/1055-9965.EPI-04-0918","article-title":"Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology","volume":"14","author":"McIntyre-Seltman","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2008.01.008_bib9","first-page":"1021","article-title":"An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV)","volume":"10","author":"Castle","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2008.01.008_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenase 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ygyno.2004.12.020","article-title":"The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma","volume":"97","author":"Dai","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1200\/JCO.2005.09.112","article-title":"Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention","volume":"23","author":"Dannenberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib13","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1158\/0008-5472.CAN-06-4273","article-title":"Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor\/coactivator exchange","volume":"67","author":"Subbaramaiah","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2008.01.008_bib14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.22428","article-title":"Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma","volume":"109","author":"Zijlmans","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2008.01.008_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.onc.1206043","article-title":"NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix","volume":"22","author":"Nair","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2008.01.008_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4161\/rna.1.1.896","article-title":"Induction of the interferon-inducible RNA-degrading enzyme, RNase L, by stress-inducing agents in the human cervical carcinoma cells","volume":"1","author":"Pandey","year":"2004","journal-title":"RNA Biology"},{"key":"10.1016\/j.ygyno.2008.01.008_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/dc.20514","article-title":"Upregulation of nuclear factor-kappaB (NF-kappaB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer","volume":"34","author":"Branca","year":"2006","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib18","unstructured":"Weinberg R. The biology of cancer. New York, NY: Garland Science, Taylor Francis Group, LLC; 2007."},{"key":"10.1016\/j.ygyno.2008.01.008_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev.med.57.121304.131253","article-title":"NSAIDs and cancer prevention: targets downstream of COX-2","volume":"58","author":"Cha","year":"2007","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ygyno.2008.01.008_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00917497","article-title":"Decrease in interferon-gamma production by peripheral blood mononuclear cells in patients with uterine cervical cancer","volume":"10","author":"Mori","year":"1990","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib21","first-page":"601","article-title":"Immunomodulating capacity of the monocyte\u2013macrophage system in patients with uterine cervical cancer","volume":"40","author":"Ohshika","year":"1988","journal-title":"Nippon Sanka Fujinka Gakkai Zasshi \u2014 Acta Obstetrica et Gynaecologica Japonica"},{"key":"10.1016\/j.ygyno.2008.01.008_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0090-8258(03)00224-5","article-title":"Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes","volume":"90","author":"Kim","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib23","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.20.4.973","article-title":"Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients","volume":"20","author":"Ferrandina","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib24","first-page":"18","article-title":"Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results","volume":"18","author":"Govindan","year":"2004","journal-title":"Oncology (Huntington)"},{"key":"10.1016\/j.ygyno.2008.01.008_bib25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0360-3016(02)03821-X","article-title":"High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy","volume":"55","author":"Kim","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2008.01.008_bib26","first-page":"1609","article-title":"Predicting the outcome of squamous cell carcinoma of the uterine cervix using combinations of individual tumor marker expressions","volume":"27","author":"Lindstrom","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2008.01.008_bib27","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/1078-0432.CCR-0497-03","article-title":"Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival","volume":"10","author":"Kim","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.01.008_bib28","first-page":"241","article-title":"VEGF-C, VEGFR-3, and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro","volume":"18","author":"Shi","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ygyno.2008.01.008_bib29","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1054\/bjoc.2000.1319","article-title":"Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix","volume":"83","author":"Lancaster","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2008.01.008_bib30","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0006-291X(02)02707-9","article-title":"Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells","volume":"299","author":"Guo","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ygyno.2008.01.008_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.neo.7900127","article-title":"Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis","volume":"3","author":"Gallo","year":"2001","journal-title":"Neoplasia (New York)"},{"key":"10.1016\/j.ygyno.2008.01.008_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3835(02)00519-0","article-title":"The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell","volume":"189","author":"Kim","year":"2003","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ygyno.2008.01.008_bib33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00432-004-0567-6","article-title":"Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target","volume":"130","author":"Kim","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijrobp.2005.06.007","article-title":"Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib","volume":"63","author":"Raju","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2008.01.008_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ijrobp.2003.09.061","article-title":"Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors","volume":"58","author":"Nakata","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2008.01.008_bib36","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0360-3016(02)03023-7","article-title":"In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations","volume":"54","author":"Raju","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2008.01.008_bib37","first-page":"665","article-title":"Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines","volume":"23","author":"Hashitani","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1196\/annals.1397.014","article-title":"The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma","volume":"1095","author":"Kwak","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ygyno.2008.01.008_bib39","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1158\/1078-0432.CCR-04-1741","article-title":"A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable\/unresectable non-small cell lung cancer","volume":"11","author":"Liao","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.01.008_bib40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11060-004-9179-x","article-title":"Phase I\/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases","volume":"71","author":"Cerchietti","year":"2005","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.prostaglandins.2004.10.004","article-title":"A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer","volume":"75","author":"Blanke","year":"2005","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.ygyno.2008.01.008_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000087302","article-title":"A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer","volume":"69","author":"Pan","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2008.01.008_bib43","first-page":"4324","article-title":"Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study","volume":"9","author":"Ferrandina","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.01.008_bib44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijrobp.2006.08.024","article-title":"A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment","volume":"67","author":"Herrera","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2008.01.008_bib45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijrobp.2006.08.002","article-title":"A phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128","volume":"67","author":"Gaffney","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2008.01.008_bib46","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2008.01.008_bib47","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.106.636746","article-title":"Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas","volume":"114","author":"Solomon","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ygyno.2008.01.008_bib48","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.clinthera.2005.07.019","article-title":"Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1\u00a0week and up to 1\u00a0year in duration of patients with osteoarthritis and rheumatoid arthritis","volume":"27","author":"Matchaba","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.ygyno.2008.01.008_bib49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.amjcard.2006.07.069","article-title":"Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials","volume":"99","author":"White","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib50","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2003.10.052","article-title":"Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure","volume":"92","author":"Farley","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib51","unstructured":"Powell MPJ, Buttin BB, Gibb RK, Luck MD, Rader JS. A pilot study of celecoxib in the treatment of patients with cervical and vaginal intraepithelial neoplasia. In: American Society of Clinical Oncology; 2003. p. Abstract 1830."},{"key":"10.1016\/j.ygyno.2008.01.008_bib52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejogrb.2005.08.019","article-title":"The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II\u2013III a phase II trial","volume":"125","author":"Hefler","year":"2006","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.03.036","article-title":"A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia","volume":"103","author":"Farley","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.01.008_bib54","series-title":"Protocol GOG-0207","article-title":"A randomized double-blind phase II trial of celecoxib, a COX-2 inhibitor, in the treatment of patients with cervical intraepithelial neoplasia 3 (CIN3).","author":"Rader","year":"2005"},{"key":"10.1016\/j.ygyno.2008.01.008_bib55","first-page":"367","article-title":"Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis","author":"Kyrgiou","year":"2006","journal-title":"The Lancet"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T08:42:59Z","timestamp":1630744979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825808000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0090825808000115"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.01.008","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}